Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

Clinical Therapeutics

Volumn 25, Issue 3, 2003, Pages 980-992

  Wunderink, Richard G ^a,d   Cammarata, Sue K ^b   Oliphant, Thomas H ^b   Kollef, Marin H ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b PFIZER INC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Methodist Healthcare   (United States)

Author keywords

Empiric therapy; Linezolid; Nosocomial pneumonia; Vancomycin

Indexed keywords

AZTREONAM; LINEZOLID; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HOSPITAL INFECTION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA;

EID: 0037364869     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80118-2     Document Type: Article

References (24)

1. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 1996;153:1711-1725.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000;21:510-515.
3. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274:639-644.
4. Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: Assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996;23:538-542.
5. Fagon JY, Maillet JM, Novara A. Hospital-acquired pneumonia: Methicillin resistance and intensive care unit admission. Am J Med. 1998;104:17S-23S.
6. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42:3251-3255.
7. Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988;32:1341-1346.
8. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 1996;40:1745-1747.
9. Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1999;43:2059-2062.
10. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40:839-845.
11. Ford CW, Hamel JC, Wilson DM, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother. 1996;40:1508-1513.
12. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412.
13. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis. 2002;35:E29-E31.
14. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy. 2001;21:1010-1013.
15. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695-698.
16. Cammarata SK, Wunderink RG, Timm JA, et al. Efficacy of linezolid in patients with nosocomial pneumonia based on severity of illness as determined by baseline APACHE score. Poster presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, ON. Poster 2234.
17. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis. 1994;18:533-543.
18. Moellering RC Jr. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis. 1994;18:544-546.
19. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257-266.
20. Tobin CM, Darville JM, Thomson AH, et al. Vancomycin therapeutic drug monitoring: Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother. 2002;50:713-718.
21. Gilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy. 31st ed. Hyde Park, Vt: Antimicrobial Therapy, Inc; 2001:1-142.
22. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 2000;161:753-762.
23. Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance. J Chemother. 1999;11:426-439.
24. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000;57(Suppl 2):S4-S9.